Horime (Ezetimibe, Rosuvastatin Calcium)

Horime is indicated for several lipid‑related conditions where lowering low‑density lipoprotein cholesterol (LDL‑C) is clinically beneficial, and it may be prescribed as part of a comprehensive cardiovascular risk‑reduction strategy.

• Hypercholesterolemia, including primary (familial) forms.
• Mixed dyslipidemia with elevated LDL‑C and triglycerides.
• Primary hyperlipidemia requiring combined reduction of cholesterol synthesis and absorption.
• Prevention of cardiovascular events in patients at high or moderate risk.
• Adjunct therapy when diet and lifestyle measures alone are insufficient.
• Use in combination with other lipid‑lowering agents when target LDL‑C levels are not achieved with monotherapy.

• Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the brush‑border of enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. Rosuvastatin competitively inhibits HMG‑CoA reductase, the rate‑limiting enzyme of hepatic cholesterol synthesis, leading to up‑regulation of hepatic LDL receptors and increased clearance of circulating LDL particles. The combined effect results in additive reductions in LDL‑C and total cholesterol, thereby contributing to overall cardiovascular risk reduction.

The most frequently reported adverse reactions with Horime are generally mild, dose‑related, and reversible, while rare serious events may require prompt medical attention and discontinuation of therapy.

Common

• Headache, often mild and transient.
• Myalgia or muscle aches, sometimes accompanied by mild fatigue.
• Diarrhea or abdominal discomfort, usually resolving without intervention.
• Elevated liver enzymes (transaminases), typically asymptomatic and reversible upon discontinuation.
• Elevated creatine kinase (CK) levels, indicating muscle enzyme release without clinical symptoms.

Serious

• Rhabdomyolysis with possible renal impairment, characterized by severe muscle pain, weakness, and dark urine.
• Severe hypersensitivity reactions such as Stevens‑Johnson syndrome, toxic epidermal necrolysis, or anaphylaxis, requiring immediate medical care.

Before initiating Horime, clinicians should evaluate patient-specific factors and monitor relevant parameters throughout therapy.

• Assess baseline liver function tests; avoid use in patients with active hepatic disease.
• Evaluate renal function; dose adjustment may be needed in severe impairment.
• Review concomitant use of strong CYP3A4 inhibitors or inducers, as they can alter rosuvastatin exposure.
• Screen for a history of muscle disorders or prior statin intolerance.
• Counsel women of childbearing potential about unknown pregnancy risk and advise effective contraception.
• Monitor lipid profile and liver enzymes periodically to gauge efficacy and safety.
• Consider potential drug interactions in patients receiving fibrates, niacin, or cyclosporine.

Horime may interact with several medicines that affect its pharmacokinetics or increase the risk of adverse events.

Avoid

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) – may raise rosuvastatin concentrations.
• Cyclosporine – markedly increases rosuvastatin exposure and risk of myopathy.
• Gemfibrozil – enhances statin-related muscle toxicity.
• Concomitant use of high-dose statins (e.g., atorvastatin >80 mg) – may increase risk of myopathy.

Use with caution

• Antacids containing aluminum or magnesium – can reduce ezetimibe absorption; separate dosing by at least 2 hours.
• Warfarin – monitor INR closely as statins may potentiate anticoagulant effect.
• Niacin or high‑dose vitamin E – may increase risk of liver enzyme elevations.